Eli Lilly is dropping the development of three therapies that did not meet expectations, including an acquired gene therapy.

As the oral weight loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its ...

Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...

TransCode Therapeutics, in partnership with Quantum Leap Healthcare Collaborative, has submitted an IND application amendment ...

Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).

This comes as Upstream Bio's twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing severe asthma exacerbations.

Compass plans to submit a NDA for its psilocybin-based psychedelic, COMP360 in TRD during Q4 2026. Credit: AnastasiaNi/Shutterstock.com. Compass Pathways’ stock is ...

Nektar will now take Treg therapy, rezpeg to a Phase III trial in atopic dermatitis (AD), which is set to begin in Q2 2026.

The impact of Covid-19 pandemic included various downstream effects on health endpoints worldwide, including the increase in substance abuse.

Sanofi and Teva are already investigating the drug in Phase III trials in UC and CD. Image credit: Jo Panuwat D / Shutterstock.com Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown ...

JANX011 targets CD19-expressing B cells in blood and tissues for deep, lasting immune reset in autoimmune disease treatment. Credit: Asian Isolated / Shutterstock.com. Janux Therapeutics has dosed the ...

The study will enrol ambulatory DMD patients with mutations spanning exons 45-55. Credit: MY STOCKERS / Shutterstock.com. Precision BioSciences has received a Study May Proceed notification from the ...